Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.

Open platform

Regeneron Pharmaceuticals Says Ubamatamab Show 73% Objective Response Rate & 11-Month Median PFS In LGSOC Patients

By Reuters News16:14 (UTC), 1 October 2026 Updated

Oct 1 (Reuters) - Regeneron Pharmaceuticals, Inc. REGN.O:

UBAMATAMAB (MUC16XCD3) SHOWS A HIGH RATE OF DURABLE RESPONSES IN INITIAL STUDY OF PATIENTS WITH ADVANCED LOW-GRADE SEROUS OVARIAN CANCER (LGSOC)
REGENERON PHARMACEUTICALS, - UBAMATAMAB SHOWS 73% OBJECTIVE RESPONSE RATE AND 11-MONTH MEDIAN PFS IN LGSOC PATIENTS
REGENERON PHARMACEUTICALS, - 9-MONTH MEDIAN DURATION OF RESPONSE OBSERVED AT 800 MG UBAMATAMAB DOSE
REGENERON PHARMACEUTICALS, - TEAES OCCURRED IN 100% OF LGSOC PATIENTS; CYTOKINE RELEASE SYNDROME IN 90%, ALL GRADE 1 OR 2
REGENERON PHARMACEUTICALS, - SERIOUS TEAES GRADE 3+ IN 21% OF LGSOC PATIENTS; TRAES IN 74%; NEUTROPENIA, ANEMIA, ELEVATED LIVER ENZYMES
REGENERON PHARMACEUTICALS, - TO ADVANCE UBAMATAMAB INTO CONFIRMATORY PHASE 3 TRIAL FOR LGSOC

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.